Estrella Immunopharma Advances STARLIGHT-1 Trial, Begins Dosing Second Cohort with EB103 for Advanced B-Cell Non-Hodgkin’s Lymphomas

Reuters

05-29

<a href="https://laohu8.com/S/ESLA">Estrella Immunopharma</a> Advances STARLIGHT-1 Trial, Begins Dosing Second Cohort with EB103 for Advanced B-Cell Non-Hodgkin's Lymphomas

Estrella Immunopharma Inc., a clinical stage biopharmaceutical company, has announced the initiation of the second cohort in its Phase I/II STARLIGHT-1 trial for the CD19-redirected ARTEMIS® T-cell therapy, EB103. The trial focuses on treating patients with Advanced B-Cell Non-Hodgkin's Lymphomas. The first patient in this second cohort has already been dosed, marking a significant milestone in the study's progression. The second cohort will assess EB103 at a higher dose level following a review of safety data from the first cohort, which reported no dose-limiting toxicities or treatment-related serious adverse events. This development is part of Estrella's ongoing efforts to complete the Phase I stage of the STARLIGHT-1 trial.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Estrella Immunopharma Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250529919302) on May 29, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2539257741"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2539257741\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2539257741?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-29 20:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2539257741","market":"nz","top_or_hot":-1,"title":"Estrella Immunopharma Advances STARLIGHT-1 Trial, Begins Dosing Second Cohort with EB103 for Advanced B-Cell Non-Hodgkin’s Lymphomas","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ESLA\">Estrella Immunopharma</a> Advances STARLIGHT-1 Trial, Begins Dosing Second Cohort with EB103 for Advanced B-Cell Non-Hodgkin's Lymphomas\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ESLAW\">Estrella Immunopharma Inc.</a>, a clinical stage biopharmaceutical company, has announced the initiation of the second cohort in its Phase I/II STARLIGHT-1 trial for the CD19-redirected ARTEMIS® T-cell therapy, EB103. The trial focuses on treating patients with Advanced B-Cell Non-Hodgkin's Lymphomas. The first patient in this second cohort has already been dosed, marking a significant milestone in the study's progression. The second cohort will assess EB103 at a higher dose level following a review of safety data from the first cohort, which reported no dose-limiting toxicities or treatment-related serious adverse events. This development is part of Estrella's ongoing efforts to complete the Phase I stage of the STARLIGHT-1 trial.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Estrella Immunopharma Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250529919302) on May 29, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Estrella Immunopharma Advances STARLIGHT-1 Trial, Begins Dosing Second Cohort with EB103 for Advanced B-Cell Non-Hodgkin’s Lymphomas</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEstrella Immunopharma Advances STARLIGHT-1 Trial, Begins Dosing Second Cohort with EB103 for Advanced B-Cell Non-Hodgkin’s Lymphomas\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-05-29 20:01</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ESLA\">Estrella Immunopharma</a> Advances STARLIGHT-1 Trial, Begins Dosing Second Cohort with EB103 for Advanced B-Cell Non-Hodgkin's Lymphomas\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ESLAW\">Estrella Immunopharma Inc.</a>, a clinical stage biopharmaceutical company, has announced the initiation of the second cohort in its Phase I/II STARLIGHT-1 trial for the CD19-redirected ARTEMIS® T-cell therapy, EB103. The trial focuses on treating patients with Advanced B-Cell Non-Hodgkin's Lymphomas. The first patient in this second cohort has already been dosed, marking a significant milestone in the study's progression. The second cohort will assess EB103 at a higher dose level following a review of safety data from the first cohort, which reported no dose-limiting toxicities or treatment-related serious adverse events. This development is part of Estrella's ongoing efforts to complete the Phase I stage of the STARLIGHT-1 trial.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Estrella Immunopharma Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250529919302) on May 29, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250529:nNDL1FsY2c:1","article_id":"2539257741","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2539257741","pubTimestamp":1748520090,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Estrella Immunopharma Advances STARLIGHT-1 Trial, Begins Dosing Second Cohort with EB103 for Advanced B-Cell Non-Hodgkin's Lymphomas. Estrella Immunopharma Inc., a clinical stage biopharmaceutical company, has announced the initiation of the second cohort in its Phase I/II STARLIGHT-1 trial for the CD19-redirected ARTEMIS T-cell therapy, EB103. The trial focuses on treating patients with Advanced B-Cell Non-Hodgkin's Lymphomas. The first patient in this second cohort has already been dosed, marking a significant milestone in the study's progression. The second cohort will assess EB103 at a higher dose level following a review of safety data from the first cohort, which reported no dose-limiting toxicities or treatment-related serious adverse events. This development is part of Estrella's ongoing efforts to complete the Phase I stage of the STARLIGHT-1 trial.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to pr","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"Estrella Immunopharma推进STARLIGHT-1试验，开始对第二个队列使用EB103治疗晚期B细胞非霍奇金淋巴瘤","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ESLA":0.9},"content_text":"Estrella Immunopharma Advances STARLIGHT-1 Trial, Begins Dosing Second Cohort with EB103 for Advanced B-Cell Non-Hodgkin's Lymphomas\n    \n\nEstrella Immunopharma Inc., a clinical stage biopharmaceutical company, has announced the initiation of the second cohort in its Phase I/II STARLIGHT-1 trial for the CD19-redirected ARTEMIS® T-cell therapy, EB103. The trial focuses on treating patients with Advanced B-Cell Non-Hodgkin's Lymphomas. The first patient in this second cohort has already been dosed, marking a significant milestone in the study's progression. The second cohort will assess EB103 at a higher dose level following a review of safety data from the first cohort, which reported no dose-limiting toxicities or treatment-related serious adverse events. This development is part of Estrella's ongoing efforts to complete the Phase I stage of the STARLIGHT-1 trial.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Estrella Immunopharma Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250529919302) on May 29, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}